Lumiracoxib: new COX-2 inhibitor effective in osteoarthritis

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1403, 2003-01, pp. : 7-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Since Novartis' COX-2 inhibitor lumiracoxib [`Prexige'] has failed to demonstrate features differentiating it from the class leader celecoxib [`Celebrex; Pfizer/Pharmacia'], it could have limited market success

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 403, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Parecoxib: new COX-2 inhibitor suggested for perioperative analgesia

By  

Inpharma, Vol. 1, Iss. 1275, 2001-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

The Molecular Basis of COX-2 Versus COX-1 Selectivity of Lumiracoxib by Molecular Docking Studies

By  

Letters in Drug Design & Discovery, Vol. 4, Iss. 6, 2007-09 ,pp. : 422-425

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Pharmacology of Lumiracoxib: A Selective Cyclo-Oxygenase-2 Inhibitor

By Rordorf Christiane M.  

Clinical Pharmacokinetics, Vol. 44, Iss. 12, 2005-01 ,pp. : 1247-1266

Adis International

Access to resources Recommend Favorite

Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor

By Bannwarth Bernard   Berenbaum Francis  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 4, 2005-04 ,pp. : 521-533

Informa Healthcare

Access to resources Recommend Favorite